{"schema_version":"secwatch.filing_event.v1","accession":"0001655759-24-000137","form_type":"8-K","ticker":"ARVN","cik":"0001655759","company_name":"ARVINAS, INC.","filed_at":"2024-11-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.122612+00:00","generated_at":"2026-05-29T22:31:23.949379+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.72,"calibrated_materiality_score":0.72,"confidence":"high","headline":"Arvinas delays VERITAC-2 Phase 3 top-line data to Q1 2025","bullets":["Enrollment for vepdegestrant monotherapy trial in 2L breast cancer completed in Q4 2024.","Primary completion date reprojected from November 2024 to January 2025.","Top-line data now expected in the first quarter of 2025 instead of late 2024.","Company and Pfizer cite routine evaluation of blinded event rates for the adjustment."],"urls":{"canonical":"https://secwatch.observer/filing/0001655759-24-000137","json":"https://secwatch.observer/filing/0001655759-24-000137.json","markdown":"https://secwatch.observer/filing/0001655759-24-000137.md","text":"https://secwatch.observer/filing/0001655759-24-000137.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1655759/000165575924000137/0001655759-24-000137-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1655759/000165575924000137/arvn-20241118.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T22:31:23.949379+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}